Major Depressive Disorder
Cluster Number:
Wiki Number: PW115
Diagnosis: Major Depressive Disorder
US Patients:
World Patients: 163 Mil; 2% of world population
Sex Ratio: M;W2
Age Onset: 20s-30s; The average duration is 23 weeks, with three more during lifetime. ½ of patients will not have another episode.
Brain Area: 102 variations in the genome linked to depression; There is an extensive description of possible brain affects on depression.
Symptoms: Has at least two weeks of depressive mood; inability to enjoy pleasure; rumination; reduced sex drive, insomnia and hypersomnia
Progression: weight and appetite may be low; fatigue, social withdrawal, suicidal thoughts; delusions or sometimes hallucinations
Causes: 40%-hereditary; response to stressors, childhood abuse. The article claims general physicians miss 2/3 of depression diagnoses.
Medications: Antidepressants-for the deeply depressed; electroconvulsive therapy
Therapies: Counseling; transcranial magnetic stimulation, light therapy, exercise, light therapy,
Youtube Video: Major Depressive Disorder
Amazon or Library Book: Major Depressive Disorder
Click the book to link or order from Amazon.
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.04.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Genetic overlap between major depressive disorder and obstructive sleep apneaby Fangbo Lin on November 20, 2024
CONCLUSION: In summary, our study identified PCLO as a common gene between OSA and MDD and provided evidence that MDD causally contributes to the development of OSA. These insights enhance our understanding of the shared mechanisms underlying the comorbidity of these conditions.
- The gut microbiota-brain connection: insights into major depressive disorder and bipolar disorderby Jia Zhao on November 20, 2024
Major depressive disorder (MDD) and bipolar disorder (BD) are two of the most prevalent mood disorders that seriously jeopardize both physical and mental health. The current diagnosis of MDD and BD relies primarily on clinical symptoms. However, correctly differentiating between MDD and BD during depressive episode states remains a substantial clinical challenge. The human gut hosts a large and diverse microbiota, which plays a pivotal role in various physiological processes. Emerging evidence...
- Ayahuasca: pharmacology, safety, and therapeutic effectsby Rafael Guimarães Dos Santos on November 20, 2024
Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian countries such as Brazil, Peru, Colombia, and Ecuador. Ayahuasca is made by the decoction of two plants, which are rich in the 5-HT1A/2A partial agonist dimethyltryptamine or DMT (from the leaves of the Psychotria viridis bush) and β-carbolines such as harmine, from the stalks of the Banisteriopsis caapi vine. There is an increasing interest in the...
- Clinical Patterns of Metabolic Syndrome in First-Hospitalized Major Depressive Disorder Patients: Comparison of Antidepressant-Exposed and Drug-Naive Groupsby Si Wang on November 20, 2024
CONCLUSION: Antidepressant use was associated with greater MetS severity but did not affect overall prevalence. Antidepressants appear to modify MetS risk factors, highlighting the need to differentiate these effects from those in drug-naïve patients when developing MetS interventions for the MDD population.